The importance of Lp(a) testing
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, explains the importance of Lp(a) testing at least once in a patient’s life.
Lp(a) and coronary plaque progression: Insights from imaging
Contrast CT is a powerful tool for visualising and quantifying different types of plaque in coronary arteries. Professor Marc Dweck, University of Edinburgh, UK, reports recent research linking Lp(a) to progression of the most unstable plaques.
The Genetics of Lp(a)
Professor Florian Kronenberg, Medical University of Innsbruck, Austria, shows how genetic studies have paved the way for understanding the regulation of Lp(a) and its causal association with cardiovascular outcomes, and potential for novel targeted therapies.
Diversity in Lp(a) across ancestry and gender
More than 1 billion people worldwide are likely to have elevated Lp(a) but levels vary with ethnicity and gender. Professor Pia Kamstrup, Copenhagen University Hospital, Denmark discusses the evidence and its implications for cardiovascular risk in different populations.
Lipoprotein(a) as a CVD risk factor
A growing body of research supports the association between elevated Lp(a) and cardiovascular disease. Dr Anne Langsted, Rigshospitalet, Copenhagen, Denmark, considers the pivotal studies that are shaping current clinical practice and future expectations.
Clinical trials targeting Lp(a)
Until recent years, Lp(a) has lagged behind other atherogenic lipoproteins in the development of targeted lipid lowering therapies. That is now changing, as Professor Ioanna Gouni-Berthold, University of Cologne, Germany explains.
